Zantac and Hydroxyurea drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zantac (ranitidine hydrochloride) and Hydroxyurea (hydroxyurea). Common drug interactions include ecchymosis among females and hepatic failure among males.

The phase IV clinical study analyzes what interactions people have when they take Zantac and Hydroxyurea. It is created by eHealthMe based on reports of 83 people who take the same drugs from the FDA, and is updated regularly.

What is Zantac?

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 434,161 Zantac users. Check the latest studies of Zantac.

What is Hydroxyurea?

Hydroxyurea has active ingredients of hydroxyurea. It is often used in polycythemia vera. eHealthMe is studying from 17,240 Hydroxyurea users. Check the latest studies of Hydroxyurea.

On Aug, 08, 2026

83 people who take Zantac and Hydroxyurea together, and have interactions are studied.

Zantac and Hydroxyurea drug interactions.

What are the common drug interactions of Zantac and Hydroxyurea, by gender? *:

female:

Ecchymosis (a discoloration of the skin resulting from bleeding underneath)
Headache (pain in head)
Laryngitis (inflammation of the larynx)
Loss of proprioception (loss of senses of body and parts)
Nasal oedema (fluid collection in nose)
Nasal septum deviation (deviated nasal septum)
Nodule (a growth of abnormal tissue)
Oedema (fluid collection in tissue)
Phlebitis superficial (inflammation of the walls of a vein-superficial)
Platelet count increased

male:

Hepatic failure (liver failure)
Headache (pain in head)
Constipation
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Malignant neoplasm progression (cancer tumour came back)
Platelet count decreased
Oedema peripheral (superficial swelling)
Aggression
Alanine aminotransferase increased
Anaemia (lack of blood)

What are the common drug interactions of Zantac and Hydroxyurea, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Infusion related reaction
Pyrexia (fever)
Cholecystitis infective (infection of gallbladder capable to infect other organs)
Cough
Device related infection
Drug ineffective
Haemoglobin decreased
Impaired healing
Injection site reaction
Respiratory tract congestion (blockage on respiratory system)

20-29:

Acute respiratory distress syndrome
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Fluid overload (too much fluid in the blood)
Haemoglobin decreased
Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)
Hypotension (abnormally low blood pressure)
Hypoxia (low oxygen in tissues)
Pneumonia
Pulmonary alveolar haemorrhage (acute bleeding)

30-39:

Abdominal discomfort
Acute sinusitis
Cellulitis (infection under the skin)
Diarrhoea
Flatulence (flatus expelled through the anus)
Folliculitis (infection of hair root)
Haemorrhage intracranial (bleeding within the skull)
Jaw fracture
Nausea (feeling of having an urge to vomit)
Periorbital cellulitis (inflammation and infection of the eyelid and the skin surrounding the eye)

40-49:

Abdominal pain
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Hepatic failure (liver failure)
Constipation
Fatigue (feeling of tiredness)
Malaise (a feeling of general discomfort or uneasiness)
Vomiting
Abdominal distension
Activated partial thromboplastin time prolonged
Alanine aminotransferase increased

50-59:

Csf white blood cell count positive
Dizziness
Dyspnoea exertional (breathlessness or shortness of breath)
Fatigue (feeling of tiredness)
Headache (pain in head)
Hypoaesthesia (reduced sense of touch or sensation)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Oedema lower limb (fluid collection in tissue of lower leg)
Pyrexia (fever)

60+:

Headache (pain in head)
Dyspnoea (difficult or laboured respiration)
Dysphonia (speech disorder attributable to a disorder of phonation)
Ecchymosis (a discoloration of the skin resulting from bleeding underneath)
Laryngitis (inflammation of the larynx)
Loss of proprioception (loss of senses of body and parts)
Nasal oedema (fluid collection in nose)
Nasal septum deviation (deviated nasal septum)
Nodule (a growth of abnormal tissue)
Oedema (fluid collection in tissue)

What are the existing conditions these people have? *

Primary Myelofibrosis (primary disorder of the bone marrow): 19 people, 22.89%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 11 people, 13.25%
Pain: 8 people, 9.64%
Asthma: 8 people, 9.64%
Constipation: 7 people, 8.43%
Hyperlipidaemia (presence of excess lipids in the blood): 6 people, 7.23%
Pulmonary Embolism (blockage of the main artery of the lung): 6 people, 7.23%
Indigestion: 6 people, 7.23%
Cough: 6 people, 7.23%
High Blood Pressure: 6 people, 7.23%

* Approximation only. Some reports may have incomplete information.

Do you take Zantac and Hydroxyurea?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously